Table 1

Comparison of clinical characteristics between patients who considered phone consultation useful and those who did not

Overall population
N=220
Patients who considered phone consultation to be useful n=116Patients who did not consider phone consultation to be useful n=104P value
Gender (female)159/218 (72.9%)86/115 (74.8%)73/103 (70.9%)0.517
Age46.6 (13.6)44.9 (14.3)48.4 (12.6)0.059
SpA or PsA110/220 (50.0%)53/116 (45.7%)57/104 (54.8%)0.177
Rheumatoid arthritis47/220 (21.4%)23/116 (19.8%)24/104 (23.1%)0.557
Autoimmune diseases30/220 (13.6%)18/116 (15.5%)12/104 (11.5%)0.280
Osteoarthritis or osteoporosis11/220 (5.0%)8/116 (6.9%)3/104 (2.9%)0.173
Fibromyalgia14/220 (6.4%)8/116 (6.9%)6/104 (5.8%)0.732
Other diagnosis8/220 (3.6%)6/116 (3.6%)2/104 (1.9%)0.392
NSAID use130/220 (59.1%)67/116 (57.8%)63/104 (60.6%)0.671
csDMARD use83/220 (37.6%)48/116 (41.4%)35/104 (33.7%)0.238
bDMARD use95/220 (43.2%)47/116 (40.5%)48/104 (46.2%)0.399
VAS peripheral pain51.6 (29.7)48.6 (30.5)54.9 (28.6)0.116
VAS axial pain57.9 (31.8)52.4 (32.8)63.7 (29.8)0.011
VAS peripheral stiffness51.5 (29.5)47.2 (29.4)56.1 (29.0)0.032
VAS axial stiffness54.7 (31.9)47.6 (32.7)62.1 (29.5)0.001
VAS fatigue57.1 (29.9)54.5 (29.2)59.8 (30.5)0.208
VAS anxiety50.4 (30.1)46.9 (30.5)54.3 (29.4)0.098
VAS depression49.4 (31.4)46.5 (31.8)52.5 (30.8)0.194
  • Univariate comparisons using chi-square or T-test.

  • Results are reperesented as mean and standard deviation (continous variables) or as absolute frequency and percentage (qualitative variables).

  • bDMARD, biological disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying anti-rheumatic drug; NSAID, Non-steroidal anti-inflammatory drugs; PsA, psoriatic arthritis; SpA, spondyloarthritis; VAS, visual analogue scale (0–100 scale).